Neurocrine Biosciences, Inc.
NBIX · NASDAQNeurocrine reported FY2025 revenue of $2.86 billion and Q1 2026 revenue of $815 million, making the thesis about whether profitable neuroscience growth can broaden while pipeline and commercialization risk stay controlled.
Financials and workspace tools are for paid members.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.